Clinical characteristics and prognostic analysis of multiple primary malignant neoplasms in patients with lung cancer.
Journal
Cancer gene therapy
ISSN: 1476-5500
Titre abrégé: Cancer Gene Ther
Pays: England
ID NLM: 9432230
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
15
10
2018
accepted:
12
01
2019
revised:
02
01
2019
pubmed:
1
2
2019
medline:
31
7
2020
entrez:
1
2
2019
Statut:
ppublish
Résumé
Retrospective analysis of data from 14,528 lung cancer patients with multiple primary malignant neoplasm (MPMN) revealed that 2.5% (364/14,528) were MPMN cases and 96.2% (350/364) were diagnosed with two primary malignancies, 3.6% (13/364) with three primary malignancies, and 0.3% (1/364) with four primary malignancies. Among 350 lung cancer patients diagnosed with two primary malignancies, 26.6% (93/350) had lung cancer diagnosed first (LCF) and 73.4% (257/350) had other cancers diagnosed initially (OCF), whereas synchronous MPMN (SMPMN) accounted for 21.1% (74/350) and metachronous MPMN (MMPMN) accounted for 78.9% (276/350) of the cases. Detection of first primary neoplasms were at an early stage for LCF patients and the age of the first lung cancer diagnosis was 59.3 years vs. 55.4 years in the OCF group (P = 0.008), whereas the onset age of second primary neoplasm diagnosis was similar in both groups (62.5 and 61.6 years, P = 0.544). Median survival times of MMPMN and SMPMN patients in the LCF group were 6.83 and 2.42 years and in the OCF group 8.67 years and 2.25 years, respectively. Multivariate analysis showed that SMPMN, LCF and the age of the primary cancer diagnosed first ( ≥ 60 years) and NSCL staging > II were significant independent factors for inferior prognosis of patients.
Identifiants
pubmed: 30700800
doi: 10.1038/s41417-019-0084-z
pii: 10.1038/s41417-019-0084-z
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
419-426Références
Chen W, Zheng R, Zeng H, Zhang S. Epidemiology of lung cancer in China. Thorac Cancer. 2015;6:209–15.
doi: 10.1111/1759-7714.12169
Fan H, Shao ZY, Xiao YY, Xie ZH, Chen W, Xie H, et al. Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study. BMJ Open. 2015;5:e009419.
doi: 10.1136/bmjopen-2015-009419
Levi F, Randimbison L, Rafael BM, Manuela MC, La Vecchia C. Second primary cancers in the Vaud and Neuchatel Cancer Registries. Eur J Cancer Prev. 2015;24:150–4.
doi: 10.1097/CEJ.0000000000000085
Koubkova L, Hrstka R, Dobes P, Vojtesek B, Vyzula R. Second primary cancers—causes, incidence and the future. Klin Onkol. 2014;27:11–7.
doi: 10.14735/amko201411
Tabuchi T, Ito Y, Ioka A, Miyashiro I, Tsukuma H. Incidence of metachronous second primary cancers in Osaka, Japan: update of analyses using population-based cancer registry data. Cancer Sci. 2012;103:1111–20.
doi: 10.1111/j.1349-7006.2012.02254.x
Warren S, Gates O. Multiple primary malignant tumors: a survey of the literature and a statistical study. Cancer. 1932;16:1358–414.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.
doi: 10.1245/s10434-010-0985-4
Li F, Zhong WZ, Niu FY, Zhao N, Yang JJ, Yan HH, et al. Multiple primary malignancies involving lung cancer. BMC Cancer. 2015;15:696.
doi: 10.1186/s12885-015-1733-8
Jiao F, Yao LJ, Zhou J, Hu H, Wang LW. Clinical features of multiple primary malignancies: a retrospective analysis of 72 Chinese patients. Asian Pac J Cancer Prev Apjcp. 2014;15:331–4.
doi: 10.7314/APJCP.2014.15.1.331
Papajik T, Myslivecek M, Sedova Z, Buriankova E, Prochazka V, Raida L, et al. Synchronous second primary neoplasms detected by initial staging F-18 FDG PET/CT examination in patients with non-Hodgkin lymphoma. Clin Nucl Med. 2011;36:509–12.
doi: 10.1097/RLU.0b013e318217541d
Fujita S, Masago K, Takeshita J, Togashi Y, Hata A, Kaji R, et al. Multiple primary malignancies in patients with non-small cell lung cancer. Intern Med. 2015;54:325–31.
doi: 10.2169/internalmedicine.54.2921
Naylor GM, Gotoda T, Dixon M, Shimoda T, Gatta L, Owen R, et al. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut. 2006;55:1545–52.
doi: 10.1136/gut.2005.080358
Liu S, Dai JY, Yao L, Li X, Reid B, Self S, et al. Esophageal adenocarcinoma and its rare association with Barrett’s esophagus in Henan, China. PLoS ONE. 2014;9:e110348.
doi: 10.1371/journal.pone.0110348
Kimura T. East meets West: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians. Chin J Cancer. 2012;31:421–9.
doi: 10.5732/cjc.011.10324
Merrill RM, Feuer EJ. Risk-adjusted cancer-incidence rates (United States). Cancer Causes Control. 1996;7:544–52.
doi: 10.1007/BF00051888
Schenker JG, Levinsky R, Ohel G. Multiple primary malignant neoplasms in breast cancer patients in Israel. Cancer. 1984;54:145–50.
doi: 10.1002/1097-0142(19840701)54:1<139::AID-CNCR2820540129>3.0.CO;2-U
Grantzau T, Thomsen MS, Væth M, Overgaard J. Risk of second primary lung cancer in women after radiotherapy for breast cancer. Radiother Oncol. 2014;111:366–73.
doi: 10.1016/j.radonc.2014.05.004
Walton A, Broadbent AL. Radiation-induced second malignancies. J Palliat Med. 2008;11:1345–52.
doi: 10.1089/jpm.2008.9815
Liu YY, Chen YM, Yen SH, Tsai CM, Perng RP. Multiple primary malignancies involving lung cancer-clinical characteristics and prognosis. Lung Cancer. 2002;35:189–94.
doi: 10.1016/S0169-5002(01)00408-1
Hsieh W-C, Chen Y-M, Perng R-P. Temporal relationship between cancers of the lung and upper aerodigestive tract. Jpn J Clin Oncol. 1997;27:63–6.
doi: 10.1093/jjco/27.2.63